Vinita Subramanya1, Di Zhao2, Pamela Ouyang3, Wendy Ying3, Dhananjay Vaidya2,4, Chiadi E Ndumele3, Joao A Lima3, Eliseo Guallar2, Ron C Hoogeveen5, Sanjiv J Shah6, Susan R Heckbert7, David A Kass3, Wendy S Post2,3, Erin D Michos2,3. 1. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA. 2. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 3. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Division of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 6. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
Purpose: Cyclic guanosine monophosphate (cGMP) is a second messenger for natriuretic peptide (NP) and nitric oxide pathways; its enhancement a target for heart failure and cardiovascular disease (CVD). We evaluated whether plasma cGMP was associated with change in left ventricular mass (LVM) among individuals free of CVD and if this differed by sex.Methods and Results: In 611 men and 612 women aged 45-84 years with plasma cGMP measured at baseline and cardiac MRI performed at baseline and 10 years later, we tested associations of cGMP [log-transformed, per 1 SD increment] with LVM, adjusting for CVD risk factors and N-terminal pro-B-type-NP (NT-proBNP). Participants had mean (SD) age of 63.1(8.5) years and cGMP 4.8(2.6) pmol/mL. Cross-sectionally, higher cGMP was associated with lesser LVM, non-lin- early. In contrast, longitudinally, higher cGMP was associated with increase in LVM [1.70g (0.61, 2.78)] over 10 years. Higher cGMP was associated with greater LVM change in men [2.68g (1.57, 3.79)] but not women [0.24g ((-0.92, 1.39); p-interaction < 0.001]. Conclusion: In conclusion, in a community-based cohort, higher cGMP levels were associated with increase in LVM over 10 years independent of CVD risk factors and NT-proBNP in men, perhaps reflecting compensatory changes. Further studies are needed to understand mechanistic roles of cGMP in LV remodelling and associated sex differences.
Purpose: Cyclic guanosine monophosphate (cGMP) is a second messenger for natriuretic peptide (NP) and nitric oxide pathways; its enhancement a target for heart failure and cardiovascular disease (CVD). We evaluated whether plasma cGMP was associated with change in left ventricular mass (LVM) among individuals free of CVD and if this differed by sex.Methods and Results: In 611 men and 612 women aged 45-84 years with plasma cGMP measured at baseline and cardiac MRI performed at baseline and 10 years later, we tested associations of cGMP [log-transformed, per 1 SD increment] with LVM, adjusting for CVD risk factors and N-terminal pro-B-type-NP (NT-proBNP). Participants had mean (SD) age of 63.1(8.5) years and cGMP 4.8(2.6) pmol/mL. Cross-sectionally, higher cGMP was associated with lesser LVM, non-lin- early. In contrast, longitudinally, higher cGMP was associated with increase in LVM [1.70g (0.61, 2.78)] over 10 years. Higher cGMP was associated with greater LVM change in men [2.68g (1.57, 3.79)] but not women [0.24g ((-0.92, 1.39); p-interaction < 0.001]. Conclusion: In conclusion, in a community-based cohort, higher cGMP levels were associated with increase in LVM over 10 years independent of CVD risk factors and NT-proBNP in men, perhaps reflecting compensatory changes. Further studies are needed to understand mechanistic roles of cGMP in LV remodelling and associated sex differences.
Entities:
Keywords:
cGMP; cardiac MRI; left ventricular hypertrophy; remodelling; sex differences
Authors: Paul W Armstrong; Carolyn S P Lam; Kevin J Anstrom; Justin Ezekowitz; Adrian F Hernandez; Christopher M O'Connor; Burkert Pieske; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Adriaan A Voors; Lilin She; Vanja Vlajnic; Francine Carvalho; Luke Bamber; Robert O Blaustein; Lothar Roessig; Javed Butler Journal: JAMA Date: 2020-10-20 Impact factor: 56.272
Authors: Vinita Subramanya; Di Zhao; Pamela Ouyang; Joao A Lima; Dhananjay Vaidya; Chiadi E Ndumele; David A Bluemke; Sanjiv J Shah; Eliseo Guallar; Chike C Nwabuo; Matthew A Allison; Susan R Heckbert; Wendy S Post; Erin D Michos Journal: Maturitas Date: 2017-11-09 Impact factor: 4.342
Authors: Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Eiki Takimoto; Diego Belardi; Carlo G Tocchetti; Susan Vahebi; Gianfrancesco Cormaci; Elizabeth A Ketner; An L Moens; Hunter C Champion; David A Kass Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Di Zhao; Eliseo Guallar; Dhananjay Vaidya; Chiadi E Ndumele; Pamela Ouyang; Wendy S Post; Joao A Lima; Wendy Ying; David A Kass; Ron C Hoogeveen; Sanjiv J Shah; Vinita Subramanya; Erin D Michos Journal: J Am Heart Assoc Date: 2020-01-13 Impact factor: 5.501